文献速递认知障碍与痴呆

认知未受损者阿尔茨海默病神经病理改变的临床路径

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.
PubMed 文献 · Lancet Neurol · 2026-01-01

本文讨论抗淀粉样蛋白单克隆抗体在症状性阿尔茨海默病中显示延缓认知下降的临床获益,并关注在认知未受损但生物标志物提示ADNC者中开展检测与预防性治疗所引发的伦理、下游效应及检测准确性等问题。若治疗被证实有益并进入常规实践,仍需填补多个知识缺口以支持安全可扩展的实施。

要点

  • 抗淀粉样蛋白抗体在症状性AD中显示延缓认知下降的临床获益。
  • 认知未受损者生物标志物检测阳性可带来伦理与下游效应问题。
  • 低患病率人群中ADNC检测准确性及中间值解读存在挑战。

核心结论

  • 抗淀粉样蛋白治疗若对认知未受损ADNC者有益并常规应用,需先解决多个知识缺口以实现安全可扩展的落地。

研究设计与样本

  • 本文为Lancet Neurol综述,围绕认知未受损ADNC者的临床路径讨论检测、伦理与治疗实施问题。

主要发现

  • 症状性AD试验提示抗淀粉样蛋白治疗可能在基线AD病理水平低的亚组获益更大。
  • 正在进行的预防试验在生物标志物提示ADNC的认知未受损者中评估此类治疗。
  • 认知未受损者检测阳性或结果不确定会引发对患者和卫生系统的下游效应。
  • 检测人群ADNC患病率低及生物标志物中间浓度时,检测准确性可能受质疑。

临床怎么用

  • 对认知未受损者进行ADNC生物标志物检测及治疗前,需权衡伦理与下游影响。
  • 解读生物标志物时应考虑人群患病率低和中间浓度结果的不确定性。
  • 若预防性治疗进入常规实践,需建立安全可扩展的实施路径。

局限性

  • 抗淀粉样蛋白治疗对认知未受损ADNC者的获益尚未由预防试验证实。
  • 认知未受损人群ADNC低患病率下生物标志物检测准确性证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent approval of disease-modifying therapies for symptomatic Alzheimer's disease is a major advance for a condition with few therapeutic options. Anti-amyloid monoclonal antibodies have shown clinically meaningful benefits in slowing cognitive decline. Clinical trials in symptomatic Alzheimer's disease suggest that anti-amyloid therapies might provide the greatest benefit in subgroups who have low baseline levels of Alzheimer's disease pathology; ongoing prevention trials are evaluating these therapies in cognitively unimpaired individuals who have biomarker evidence of Alzheimer's disease neuropathological change (ADNC). However, the possibility of biomarker testing and treatment in cognitively unimpaired people raises key questions about ethics and the consequences that follow from a positive test or an uncertain result (ie, the so-called downstream effects on patients and health systems). Furthermore, test accuracy might be questioned when ADNC has a low prevalence in the population being tested and in the case of intermediate-range biomarker concentrations that might not reliably indicate true ADNC or be false positives. If anti-amyloid therapies prove beneficial for cognitively unimpaired people with ADNC and become part of routine practice, several key knowledge gaps must be addressed to support safe, scalable, real-world implementation of Alzheimer's disease treatment.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Graff-Radford J, Karliner L, Barnes DE, et al. Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change. Lancet Neurol. 2026. PMID: 42716047. doi:10.1016/S1474-4422(26)00248-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。